Matrine Cancer Research Results

Matr, Matrine: Click to Expand ⟱
Features:

Matrine — a naturally occurring tetracyclic quinolizidine alkaloid found predominantly in Sophora flavescens and related Sophora species, including Sophora tonkinensis. It is a plant-derived bioactive small molecule rather than an approved anticancer drug. Common abbreviations include Mat and MT. Matrine has broad anti-inflammatory, antifibrotic, neuroprotective and preclinical anticancer activities. Cancer studies consistently identify apoptosis, PI3K/AKT/mTOR suppression, Wnt/β-catenin inhibition, metabolic suppression, inhibition of invasion/EMT and context-dependent ROS-mediated cell death as important actions. More recent work also supports ferroptosis through pathways involving GPX4 and β-catenin/TCF7L2. Matrine should be distinguished from oxymatrine and from Compound Kushen Injection, which contains multiple constituents and has substantially more human clinical data.

Primary mechanisms (ranked):

  1. Induction of programmed cancer-cell death, particularly mitochondrial/caspase-dependent apoptosis through ↓ Bcl-2/Bax ratio, ↑ caspase-3/9 activity and suppression of survival proteins.
  2. Suppression of PI3K/AKT/mTOR signaling, reducing cancer-cell survival, proliferation and growth while contributing to apoptosis and autophagy.
  3. Suppression of Wnt/β-catenin signaling, including direct disruption of β-catenin/TCF7L2 signaling in some models, thereby reducing proliferation, metastasis and GPX4-mediated ferroptosis resistance.
  4. Suppression of tumor glycolysis and the Warburg phenotype through targets including HK2 and, in recent TNBC work, ENO1-associated glycolytic enzyme complexes.
  5. Inhibition of EMT, migration, invasion and metastasis through modulation of PTEN/AKT, β-catenin, E-cadherin, vimentin, MMP-2 and MMP-9.
  6. Induction of ROS-mediated stress signaling in susceptible cancer cells; ROS can activate p38 and contribute to apoptosis, autophagy and ferroptosis. This effect is strongly model- and concentration-dependent.
  7. Induction of ferroptosis in selected cancer models through ↓ GPX4, ↑ lipid peroxidation and, depending on tumor type, Piezo1/Ca²⁺ or β-catenin/TCF7L2 signaling.
  8. Anti-angiogenic activity through suppression of VEGF/VEGFR signaling.
  9. Chemosensitization in preclinical models, including increased cisplatin sensitivity through suppression of glycolysis/lactylation and DNA-repair-associated resistance mechanisms.

Bioavailability / PK relevance: Oral matrine has relatively unfavorable and formulation-dependent pharmacokinetics. Rat studies report absolute oral bioavailability of approximately 17%, although botanical matrices can substantially alter absorption and disposition. A small human pharmacokinetic study using a multi-component botanical preparation detected systemic matrine and reported an approximately 10-hour plasma terminal half-life, but this cannot be directly extrapolated to purified matrine dosing. Low oral exposure, rapid disposition in several animal studies and toxicity are important constraints motivating nanoparticle, liposomal and other delivery approaches.

In-vitro vs systemic exposure relevance: Many cancer-cell studies use matrine in the high-micromolar to millimolar range, frequently approximately 0.1–2 mM or higher. These concentrations are substantially above exposures that can confidently be assumed achievable following conventional oral administration. Consequently, direct translation of many in-vitro anticancer effects to oral supplementation is uncertain. Newer studies identifying direct targets at lower concentrations improve mechanistic credibility but do not yet establish a clinically achievable anticancer exposure.
-**can be heptotoxic, but selenium may alleviate the toxicity.

Clinical evidence status: Predominantly preclinical for purified matrine as an anticancer agent. Cell-culture and animal xenograft evidence is extensive, but there is no established Phase I/II oncology development program demonstrating efficacy of purified matrine. Human randomized evidence frequently cited for “matrine” actually concerns Compound Kushen Injection, a multi-component Sophora flavescens-based preparation used adjunctively with chemotherapy in China; those results cannot be attributed specifically to matrine. Matrine is therefore best classified as a preclinical/investigational anticancer compound rather than an established adjunct cancer therapy. Hepatotoxicity and neurotoxicity are important dose-limiting safety concerns.

Matrine Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Apoptosis / Bcl-2 / Bax / Caspases ↓ Bcl-2/Bax; ↑ Bax; ↑ caspase-3/9; ↑ apoptosis Lower cytotoxicity reported in some comparative cell models Programmed tumor-cell death One of the most reproducible matrine anticancer phenotypes across tumor types.
2 PI3K / AKT / mTOR ↓ PI3K; ↓ p-AKT; ↓ mTOR signaling Context-dependent ↓ survival and proliferation; ↑ apoptosis/autophagy Central signaling axis supported in lung, breast, liver and other cancer models.
3 Wnt / β-catenin / TCF7L2 ↓ β-catenin signaling; ↓ β-catenin/TCF7L2 complex Not adequately characterized ↓ proliferation and metastasis; ↑ ferroptosis Recent evidence supports β-catenin as a direct matrine target in TNBC; inhibition can reduce GPX4 transcription.
4 Glycolysis / Warburg Effect / HK2 / ENO1 ↓ HK2; ↓ ENO1-associated glycolytic complex; ↓ glycolytic flux; ↓ lactylation Not adequately characterized Metabolic suppression and apoptosis HK2 suppression is established in myeloid leukemia. Recent TNBC evidence identifies ENO1 as a direct target relevant to cisplatin resistance.
5 EMT / PTEN / AKT / MMP-2 / MMP-9 ↑ PTEN; ↓ AKT; ↑ E-cadherin; ↓ vimentin; ↓ MMP-2/9 Not adequately characterized ↓ migration, invasion and metastasis Supported across breast, hepatocellular, cervical and colorectal cancer models.
6 Ferroptosis / GPX4 / Lipid Peroxidation ↓ GPX4; ↑ Fe²⁺; ↑ lipid ROS; ↑ ferroptosis Uncertain Iron-dependent cancer-cell death Demonstrated in cervical cancer and TNBC models. Mechanism is tumor-context dependent.
7 ROS / p38 Stress Signaling ↑ ROS; ↑ p38 activation; ↑ apoptosis Variable; antioxidant effects reported in non-cancer disease models Oxidative-stress-mediated cell death ROS scavenging with NAC can attenuate matrine-induced apoptosis in susceptible cancer models. ROS direction is highly context-dependent outside cancer.
8 Ca²⁺ / Piezo1 / Ferroptosis ↑ Piezo1; ↑ Ca²⁺ influx; ↑ lipid peroxidation; ↑ ferroptosis Not established Ferroptotic cell death Mechanistically demonstrated in cervical cancer; should be considered a contextual rather than universal matrine mechanism.
9 Autophagy / AMPK / AKT / mTOR ↑ LC3-II; ↑ Beclin-1; ↓ p62; ↑ autophagy Context-dependent Stress response and tumor growth inhibition Autophagy may contribute to or oppose apoptosis depending on model and treatment conditions.
10 VEGF / VEGFR Angiogenesis ↓ VEGF; ↓ VEGFR signaling; ↓ microvessel density Not adequately characterized ↓ tumor angiogenesis Observed in breast-cancer xenografts and linked with AKT/NF-κB and Wnt/β-catenin modulation.
11 NF-κB Signaling Usually ↓ IKKβ / NF-κB activity; context-dependent activation also reported Context-dependent ↓ survival, inflammation and invasion Direction is not uniform. In HepG2 cells matrine-induced NF-κB activation appeared protective because NF-κB inhibition increased matrine-induced apoptosis.
12 Chemosensitization ↑ sensitivity to cisplatin and selected anticancer agents (model-dependent) Insufficient evidence Potential reversal of treatment resistance Recent TNBC work links cisplatin sensitization to direct ENO1 targeting, ↓ glycolysis/lactylation and impaired resistance-associated DNA repair. Primarily preclinical evidence.
13 Clinical Translation Constraint High experimental concentrations frequently required Hepatotoxicity and neurotoxicity possible at excessive exposure Limits systemic therapeutic window Low oral bioavailability, uncertain human tumor exposure, formulation dependence and toxicity remain major barriers. Clinical findings with Compound Kushen Injection cannot be attributed specifically to matrine.




Alzheimer's disease relevance: Matrine has meaningful but entirely preclinical evidence in Alzheimer’s disease models. Reported effects include inhibition of Aβ aggregation, interference with the RAGE/Aβ axis, reduction of Aβ deposition, suppression of microglial activation and NADPH-oxidase-derived oxidative stress, reduction of inflammatory cytokines, and improvement of learning and memory in rodent models. No convincing human therapeutic evidence establishes matrine as an AD treatment.

Clinical evidence status: Preclinical only. The strongest evidence consists of cellular Aβ studies and multiple rodent AD models; clinical efficacy, dosing, long-term neurological safety and achievable CNS exposure remain undetermined.

Matrine in Alzheimer's Disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Aβ Aggregation ↓ Aβ42 aggregation; ↑ disaggregation of immature oligomers ↓ amyloid-associated cytotoxicity Demonstrated in biochemical/cellular systems and supported by reduced Aβ deposition in animal models.
2 RAGE / Aβ Axis ↓ RAGE/Aβ signaling ↓ Aβ-mediated neuronal injury and inflammation A prominent mechanism in an AD transgenic-mouse study.
3 Microglial Activation / Neuroinflammation ↓ microglial activation; ↓ TNF-α; ↓ IL-1β; ↓ IL-6 ↓ neuroinflammation Associated with improved learning and memory in Aβ-induced mouse models.
4 NADPH Oxidase / ROS ↓ gp91phox; ↓ p47phox; ↓ ROS ↓ oxidative neuronal stress Notable contrast with the pro-oxidant ROS response reported in several cancer-cell models.
5 Th17 / Treg Balance ↓ IL-17A; ↓ IL-23; ↓ RORγt; ↑ TGF-β; ↑ IL-35; ↑ Foxp3 Immune modulation Reported in an Aβ1-42 rat model together with improved cognitive performance.
6 Clinical Translation Constraint Human efficacy unknown Preclinical evidence only CNS exposure, effective human dose, chronic safety and clinical benefit have not been established.


Scientific Papers found: Click to Expand⟱
8565- Matr,    Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway
- in-vitro, AML, THP1
tumCV↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓,
8551- Matr,    Research Progress of Natural Matrine Compounds and Synthetic Matrine Derivatives
- Review, Nor, NA
*BioAv↓, *toxicity↑, *AntiTum↑, *AntiViral↑, *Inflam↓, *hepatoP↑, *Analgesic↑, *Half-Life↓, *toxicity↓,
8552- Matr,    Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways
- Review, AD, NA
*BBB↑, *neuroP↑, *HMGB1↓, *NF-kB↓, *MyD88↓, *TLR4↓, *TRAF6↓, *Cyt‑c↓, *MDA↓, *Beclin-1/ATG6↑, *GPx↑, *IL23↓, *IL17↓, *NRF2↑, *HO-1↑, *SOD↑, *GSH↑, *Stroke↓, *BACE/β-secretase↓, *Aβ↓, *BDNF↑, *AChE↓, *BChE↓, *ROS↓, *memory↑, *NP/CIPN↓,
8553- Matr,    Research progress on the pharmacological effects of matrine
- Review, Nor, NA
*AntiCan↑, *antiAll↑, *Stroke↓, TumCI↓, TumCMig↓, TumCP↓, TumCCA↑, *AGEs↓, *Inflam↓, *antiOx↑, *neuroP↑, *Apoptosis↓, *IBI↑, *GutMicro↑, EGFR↓, *HSP60/HSPD1↓, *antiOx↑, *GSH↑, *Catalase↑, *AChE↓, *BChE↓, *neuroP↑, *PI3K↑, *Akt↑, *mTOR↑, *cognitive↑, *ROS↓, *toxicity↑,
8554- Matr,    Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation
- in-vitro, PC, Capan1 - in-vitro, PC, MIA PaCa-2
TumCP↓, TumCCA↑, Apoptosis↑, CAIX/CA9↓, CAXII/CA12↑,
8555- Matr,    Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
- Review, Var, NA
*AntiTum↑, *Inflam↓, *Analgesic↑, *AntiViral↑, *Imm↑, *PI3K↑, *Akt↑, *mTOR↑, TumAuto↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, PTEN↑, TumCP↓, TumCMig↓, TumCI↓, ChemoSen↑, ROS↑, uPA↓, p‑ERK↓, cachexia↓, antiD↑, GSK‐3β↓, LC3B-II↑, p62↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, FOXO1↑, FOXO3↑, FOXO4↑, PARP↑, BIM↑, Bcl-2↓, survivin↓, miR-21↓, *HOTAIR↑, *p‑Akt↑, *p‑STAT3↑, *STAT3↑, *ROS↓, Wnt↓, β-catenin/ZEB1↓, NOTCH1↓, JAG1↓, HES1↓, BioAv↝, toxicity↝,
8556- Matr,    Matrine alleviates spatial learning and memory impairment in diabetic mice by inhibiting endoplasmic reticulum stress and through modulation of PK2/PKRs pathway
- in-vivo, AD, NA - in-vivo, Diabetic, NA
*AntiTum↑, *AntiDiabetic↑, *cardioP↑, *neuroP↑, *glucose↓, *Learn↑, *memory↑, *ER Stress↓, *GRP78/BiP↓, *CHOP/DDIT3↓, *ATF6↓, *Casp12↓, *PROK2↑, *PROKR1↑, *PROKR2↑,
8557- Matr,    Effects of matrine in combination with cisplatin on liver cancer
- in-vivo, Liver, HepG2
ChemoSen?, TumW↓, TumVol↓, survivin↓, XIAP↓, Casp3↑, Casp7↑, Casp9↑,
8558- Matr,    Matrine exerts anti‑breast cancer activity by mediating apoptosis and protective autophagy via the AKT/mTOR pathway in MCF‑7 cells
- in-vitro, BC, MCF7
TumCG↓, TumAuto↑, LC3B-II↑, p62↓, Akt↓, mTOR↓,
8559- Matr,    Matrine induces toxicity in mouse liver cells through an ROS-dependent mechanism
- vitro+vivo, Nor, NA
*Dose↝, *toxicity↑, *Casp3↑, *Casp9↑, *ROS↑, *MMP↓, *ATP↓, *eff↓,
8560- Matr,    Matrine: A Promising Natural Product With Various Pharmacological Activities
- Review, AD, NA - Review, Stroke, NA - Review, Var, NA
*antiAll↑, *Stroke↓, *AntiArt↑, TumCCA↑, VEGF↓, Apoptosis↑, P53↑, P21↑, PCNA↓, EIF4E↓, TumCP↓, TumCMig↓, IAP1↓, ROS↑, EMT↓, PAX2↓, ER Stress↑, HK2↓, Apoptosis↑, STAT3↓, mtDam↑, HMGB1↓, ChemoSen↑, p‑GSK‐3β↓, P-gp/ABCB1↓, MRP1/ABCC1↓, Vim↓, cycD1/CCND1↓, CDK4↓, GSH↓, SOD↓, mt-Cyt‑c↓, BAX↑, MMP9↓, MMP2↓, E-cadherin↓, N-cadherin↓, FOXO1↓, FOXO3↓, FOXO4↓, PI3K↓, ATF4↑, CHOP/DDIT3↑, *Aβ↓, *RAGE↓, *memory↑, *Learn↑, *cognitive↑, *MDA↓, *SOD↑, *GPx↑, *Catalase↑, *antiAll↑, *AHR↓, *SOCS-3↓, *ICAM-1↓, *ROS↓, cachexia↓, *BACE/β-secretase↓, *NF-kB↓, *TNF-α↓, *IL1β↓,
8561- Matr,    Matrine triggers colon cancer cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22
- in-vitro, Colon, SW480 - in-vitro, CRC, SW-620
Dose↝, tumCV↓, Apoptosis↑, TumCCA↑, miR-22↑, Wnt↓, β-catenin/ZEB1↓, MEK↓, ERK↓,
8563- Matr,    Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231
TumCP↓, Apoptosis↑, EMT↓, ITGB1↓,
8564- Matr,    Matrine inhibits proliferation and promotes autophagy and apoptosis in non-small cell lung cancer cells by deactivating PI3K/AKT/mTOR pathway
- in-vitro, Lung, A549
TumCP↓, p‑Akt↓, p‑mTOR↓, LC3B↑, PI3K↓, Akt↓, mTOR↓,
8550- Matr,    Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway
- vitro+vivo, Liver, HUH7
other↝, Wnt↓, β-catenin/ZEB1↓, EMT↓, TumCMig↓, TumCI↓, Inflam↓, hepatoP↑, AST?, ALB↑, ALAT↓, ALP↓, GGT/CD224↓, TBIL↓, DBIL↓, IBIL↓,
8566- Matr,    Matrine suppresses lung metastasis of human hepatocellular carcinoma by directly targeting matrix metalloproteinase-9
- vitro+vivo, HCC, MHCC-97H
TumCMig↓, TumCI↓, Dose↓, MMP9↓, TumMeta↓,
8567- Matr,    Matrine induces apoptosis in multiple colorectal cancer cell lines in vitro and inhibits tumour growth with minimum side effects in vivo via Bcl-2 and caspase-3
- vitro+vivo, CRC, NA
TumCP↓, TumCCA↑, Bcl-2↓, BAX↑, cl‑Casp3↑, TumCG?, toxicity↓,
8568- Matr,    Matrine induces apoptosis via targeting CCR7 and enhances the effect of anticancer drugs in non-small cell lung cancer in vitro
- in-vitro, NSCLC, A549
tumCV↓, P53↑, BAX↑, Casp3↑, Bcl-2↓, CCR7↓, ChemoSen↑,
8569- Matr,    Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathway
- vitro+vivo, Cerv, NA
TumCG↓, Apoptosis↑, TumCI↓, TumCMig↓, MMP2↓, MMP9↓, p38↓, TumCG↓, TumMeta↓,
8570- Matr,    Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway
- vitro+vivo, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCMig↓, TumCI↓, MMP9↓, MMP2↓, p‑p65↓, NF-kB↓,
8571- Matr,    Effect of Matrine on HPAC cell migration by down-regulating the expression of MT1-MMP via Wnt signaling
- in-vitro, PC, Capan1
Dose↝, TumCP↓, Wnt↓, β-catenin/ZEB1↓, MMP14↓,
8572- Matr,    Matrine induces mitochondrial apoptosis in cisplatin-resistant non-small cell lung cancer cells via suppression of β-catenin/survivin signaling
- in-vitro, Lung, A549 - in-vitro, Lung, H460
Dose?, β-catenin/ZEB1↓, survivin↓, MMP↓, Casp9↑, Casp3↑,
8573- Matr,    Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-κB signaling pathway
- in-vitro, BC, MCF7 - in-vitro, BC, BT20 - in-vitro, BC, MDA-MB-231
TumCD↑, IKKα↓,
8574- Matr,    Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration
- in-vitro, Lung, A549 - ex-vivo, HCC, SMMC-7721 cell
TumCG↓, Bcl-2↓, BAX↑, TumCMig↓, tumCV∅, VEGF↓, Synergy↑,
8575- Matr,    Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3
- in-vitro, GC, SGC-7901
TumPF↓, Apoptosis↑, Fas↑, FasL↑, Casp3↑,
8576- Matr,    Matrine reduces the proliferation and invasion of colorectal cancer cells via reducing the activity of p38 signaling pathway
- vitro+vivo, CRC, NA
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, p‑p38↓, TumMeta↓,
8577- Matr,  Cisplatin,    Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer
- Review, GC, NA
ChemoSen↑, QoL↑, chemoP↑,
8549- Matr,    Matrine disrupts Nrf2/GPX4 antioxidant system and promotes hepatocyte ferroptosis
- in-vitro, Var, NA
toxicity↑, *hepatoP↓, *SOD↓, *GSH↓, *MDA↑, *ROS↑, *lipid-P↑, *Iron↝, *Ferroptosis↑, *FTH1↓, *NRF2↓, *xCT/SLC7A11↓, *GPx4↓, *HO-1↓, *toxicity↝,
8526- Matr,    A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine
- Review, Nor, NA
*AntiCan↑, *Inflam↓, *antiOx↑, *AntiViral↑, *Bacteria↓, *antiAll↑, *Analgesic↑, *hepatoP↑, *cardioP↑, *neuroP↑, *toxicity↝, p38↓, IL6↓, JAK2↓, STAT3↓, Casp↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, PCNA↓, Bcl-2↓, XIAP↑, VEGF↓, NF-kB↓, MMP2↓, MMP9↓, P-gp/ABCB1↓, survivin↓, OCT4↓, SOX2↓, p62↓, *TNF-α↓, *IL6↓, *HMGB1↓, *AntiArt↑, *NF-kB↓, *IL6↓, *IL8↓, *IL1β↓, *IL17↓, *TNF-α↓, *ROS↓, *NRF2?, *AST↓, *ALAT↓, *TGF-β↓, *α-SMA↓, *JAK2↑, *STAT3↑, *BioAv↝, *Half-Life↝, ChemoSen↑, ATP↓, ROS↑,
8527- Matr,    Matrine Promotes Human Myeloid Leukemia Cells Apoptosis Through Warburg Effect Mediated by Hexokinase 2
- in-vitro, AML, K562
TumCP↓, Apoptosis↑, Warburg↓, HK2↓, Synergy↑, Glycolysis↓,
8528- Matr,  Cisplatin,    Matrine targets Enolase 1 and regulates the glycolysis-lactylation axis to enhance cisplatin sensitivity in triple-negative breast cancer
- vitro+vivo, BC, NA
ChemoSen↑, ENO1↓, Glycolysis↓, lactateProd↓,
8529- Matr,    Matrine targets β-catenin and blocks the formation of β-catenin/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancer
- in-vitro, BC, NA
β-catenin/ZEB1↓, Wnt↓, TCF7/TCF1↓, GPx4↝, Ferroptosis↑, EMT↓,
8530- Matr,    Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition
- in-vitro, HCC, NA
TumCP↓, TumCMig↓, TumCI↓, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, EMT↓, PIP3↑, PTEN↑, p‑Akt↓,
8531- Matr,    Matrine: A review of its pharmacology, pharmacokinetics, toxicity, clinical application and preparation researches
- Review, Nor, NA
*AntiCan?, *Inflam?, *Bacteria↓,
8532- Matr,    Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cells
- in-vitro, NSCLC, NA
Apoptosis↑, Casp↑, p38↓, ROS↑, eff↓,
8533- Matr,    Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway
- in-vitro, Lung, A549 - in-vitro, Lung, 95D
TumCP?, Apoptosis?, PI3K↓, Akt↓, mTOR↓, IAP1↓,
8534- Matr,    Matrine induces apoptosis and autophagy in human lung adenocarcinoma cells via upregulation of Cavin3 and suppression of PI3K/AKT pathway
- in-vitro, Lung, A549 - in-vitro, Nor, MRC-5
TumCP↓, selectivity↑, Apoptosis↑, BAX↑, Bcl-2↓, TumAuto?, LC3II↑, Beclin-1/ATG6↑, p62↓, Cavin3↓, p‑PI3K↓, p‑Akt↓,
8535- Matr,    Matrine induces ferroptosis in cervical cancer through activation of piezo1 channel
- in-vitro, Cerv, NA
TumCG↓, *toxicity↓, Ferroptosis↑, GPx4↓, lipid-P↑, Iron↓, ROS↑, Piezo1↑,
8536- Matr,    Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/β-catenin pathway
- vitro+vivo, BC, 4T1 - in-vitro, BC, MCF7
tumCV↓, Apoptosis↑, VEGF↓, Wnt↓, β-catenin/ZEB1↓, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, angioG↓,
8537- Matr,    Matrine restrains the development of colorectal cancer through regulating the AGRN/Wnt/β-catenin pathway
- vitro+vivo, CRC, NA
TumCG↓, AGRN↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓,
8538- Matr,    Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling
- in-vitro, BC, MDA-MB-231 - ex-vivo, BC, MDA-MB-231
TumCP↓, Synergy↑, Apoptosis?, Bax:Bcl2↑, TumCI↓, MMP9↓, MMP2↓, Akt↓, NF-kB↓, VEGFR1↓, BioAv↝,
8539- Matr,    Matrine ameliorates cognitive deficits via inhibition of microglia mediated neuroinflammation in an Alzheimer's disease mouse model
- in-vivo, AD, NA
*Inflam↓, *Dose↝, *memory↑, *Learn↑, *ROS↓, *TNF-α↓, *IL1β↓, *IL6↓,
8540- Matr,    Matrine improves cognitive impairment and modulates the balance of Th17/Treg cytokines in a rat model of Aβ1-42-induced Alzheimer's disease
- in-vivo, AD, NA
*Inflam↓, *neuroP↑, *Learn?, *memory?,
8541- Matr,    Matrine induces ferroptosis and suppresses colorectal cancer through targeting the STAT3/SLC7A11 pathway
- in-vivo, CRC, NA
TumCP↓, necrosis↑, Ferroptosis↑, TumCD↑, lipid-P↑, MDA↑, GSH↓, xCT/SLC7A11↓, P53↑, p‑STAT3↓,
8542- Matr,    Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling
- vitro+vivo, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, p‑PI3K↓, CHK1↓, p‑Akt↓, Bcl-2↓, MTA1↓, Vim↓, MMP2↓, MMP9↓, γH2AX↑, E-cadherin↑, BAX↑, cl‑Casp3↑, Ki-67↓, TumCG↓,
8543- Matr,    Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K/AKT signaling pathway
- in-vitro, RPE/RB, Y79
TumCMig↓, Apoptosis↑, NR1D2↓, BAX↑, cl‑Casp3↑, Bcl-2↓, p‑PI3K↓, p‑Akt↓,
8544- Matr,    Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential
- Review, BC, NA
*hepatoP↑, *Inflam↓, *ROS↓, *ER Stress↓, *lipid-P↓, TumCP↓, TumCI↓, TumCMig↓, TumAuto↑, Apoptosis↑, *AST↓, *ALAT↓, *SOD↑, *MDA↓, *TNF-α↓, *IL6↓, *NRF2↑, *HO-1?, *NF-kB↓, *Inflam↓, AFP?, PCNA↓, cMyc↓, Bcl-2↓, BAX↑, EMT↓, MDM2↓, P53↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, NOTCH↑, ChemoSen↑, eff↑, survivin↓, XIAP↓, Synergy↑,
8545- Matr,    Matrine enhances RLS3-induced ferroptosis at non-toxic doses in acute myeloid leukemia cells with MLL rearrangement
- in-vitro, AML, MV411 - in-vitro, ALL, MOLM-13
Ferroptosis↑, Synergy↑, i-Iron↑, ROS↑, MMP↓, GSH↓, xCT/SLC7A11↓, GPx4↓, P53↑,
8546- Matr,    Matrine Attenuates Neurological Deficits and Neuroinflammation by Inhibiting the HMGB1/RAGE Axis and Ferroptosis in Intracerebral Hemorrhage Mice
- in-vivo, Stroke, NA
*Dose?, *Stroke↓, *BBB↝, *TJ↑, *ZO-1↑, *OCLN↑, *CLDN4↑, *HMGB1↓, *RAGE↓, *JNK↓, *p38↓, *ERK↓, *NF-kB↓, *IL1β↓, *IL6↓, *TNF-α↓, *BAX↓, *Bcl-2↑, *Apoptosis↓, *Iron↓, *ACSL4↓, *GPx4↑, *Ferroptosis↓, *neuroP↑, *Inflam↓, *antiOx↑,
8547- Matr,    Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategies
- Review, Var, NA
*Ingr↝, *AntiTum↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, TumCMig↓, TumCI↓, JPT1/HN1↓, Erlin1↑, LINC01116↓, miR-592↑, ERK↓, JAK↓, STAT3↓, miR-182-5p↓, PI3K↓, Akt↓, Wnt↓, β-catenin/ZEB1↓, Sharpin↓, ROS↓, AMPK↑, mTOR↓, Snail↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, E-cadherin↑, PTEN↑, miR-10b-5p↓, GPx4↓, lipid-P↑, Iron↑, Piezo1↑,

Showing Research Papers: 1 to 50 of 53
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 53

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GPx4↓, 3,   GPx4↝, 1,   GSH↓, 3,   Iron↓, 1,   Iron↑, 1,   i-Iron↑, 1,   lipid-P↑, 3,   MDA↑, 1,   ROS↓, 1,   ROS↑, 6,   SOD↓, 1,   xCT/SLC7A11↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   ATP↓, 1,   CAIX/CA9↓, 1,   ENO1↓, 1,   Glycolysis↓, 2,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HK2↓, 3,   lactateProd↓, 1,   PIP3↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis?, 2,   Apoptosis↑, 16,   BAX↑, 8,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   BIM↑, 1,   Casp↑, 2,   Casp3↑, 5,   cl‑Casp3↑, 4,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 3,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,   mt-Cyt‑c↓, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 5,   IAP1↓, 2,   MDM2↓, 1,   necrosis↑, 1,   p38↓, 3,   p‑p38↓, 1,   survivin↓, 5,   TumCD↑, 2,   XIAP↓, 2,   XIAP↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   p‑Akt↓, 6,   Cavin3↓, 1,   EGFR↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   IKKα↓, 1,   JAK↓, 1,   JAK2↓, 1,   MEK↓, 1,   mTOR↓, 7,   p‑mTOR↓, 2,   PI3K↓, 7,   p‑PI3K↓, 4,   PTEN↑, 3,   STAT3↓, 3,   p‑STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cMyc↓, 1,   FOXO1↓, 1,   FOXO1↑, 1,   FOXO3↓, 1,   FOXO3↑, 1,   FOXO4↓, 1,   FOXO4↑, 1,   HES1↓, 1,   JPT1/HN1↓, 1,   LINC01116↓, 1,   miR-10b-5p↓, 1,   miR-182-5p↓, 1,   miR-21↓, 1,   miR-22↑, 1,   miR-592↑, 1,   NR1D2↓, 1,   OCT4↓, 1,   other↝, 1,   PAX2↓, 1,   SOX2↓, 1,   tumCV↓, 4,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   Erlin1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 4,   LC3B↑, 1,   LC3B-II↑, 2,   LC3II↑, 1,   p62↓, 4,   TumAuto?, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 5,   PARP↑, 1,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CHK1↓, 1,   cycD1/CCND1↓, 1,   Ki-67↓, 1,   P21↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EIF4E↓, 1,   JAG1↓, 1,   Ki-67↓, 1,   NOTCH↑, 1,   NOTCH1↓, 1,   Piezo1↑, 2,   TumCG?, 1,   TumCG↓, 8,   TumCP?, 1,   TumCP↓, 17,   Wnt↓, 8,  

Migration(tgid=13) ⓘ

AGRN↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   EMT↓, 6,   ITGB1↓, 1,   MMP14↓, 1,   MMP2↓, 10,   MMP9↓, 11,   MTA1↓, 1,   N-cadherin↓, 2,   Sharpin↓, 1,   Slug↓, 2,   Snail↓, 3,   TumCI↓, 13,   TumCMig↓, 15,   TumMeta↓, 3,   TumPF↓, 1,   uPA↓, 1,   Vim↓, 5,   β-catenin/ZEB1↓, 9,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 4,   VEGFR1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCR7↓, 1,   HMGB1↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 3,   p‑p65↓, 1,   TCF7/TCF1↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

CAXII/CA12↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 2,   ChemoSen?, 1,   ChemoSen↑, 7,   Dose?, 1,   Dose↓, 1,   Dose↝, 2,   eff↓, 2,   eff↑, 1,   MRP1/ABCC1↓, 1,   P-gp/ABCB1↓, 2,   selectivity↑, 1,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   ALAT↓, 1,   ALB↑, 1,   ALP↓, 1,   AST?, 1,   DBIL↓, 1,   EGFR↓, 1,   IBIL↓, 1,   IL6↓, 1,   TBIL↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiD↑, 1,   cachexia↓, 2,   chemoP↑, 1,   hepatoP↑, 1,   QoL↑, 1,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 188

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 2,   GPx↑, 2,   GPx4↓, 1,   GPx4↑, 2,   GSH↓, 1,   GSH↑, 3,   HO-1?, 1,   HO-1↓, 1,   HO-1↑, 1,   Iron↓, 1,   Iron↝, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 3,   MDA↑, 1,   NRF2?, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 7,   ROS↑, 2,   SOD↓, 1,   SOD↑, 3,   xCT/SLC7A11↓, 1,   xCT/SLC7A11↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

HSP60/HSPD1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   ALAT↓, 2,   ALAT↑, 1,   ATP↓, 1,   CYP51/14LDM↑, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   BAX↓, 1,   Bcl-2↑, 1,   Casp12↓, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 2,   Ferroptosis↑, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 2,   p‑Akt↑, 1,   ERK↓, 1,   JAK2↑, 1,   JNK↓, 1,   mTOR↑, 2,   PI3K↑, 2,   PROKR1↑, 1,   PROKR2↑, 1,   STAT3↑, 2,   p‑STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HOTAIR↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↓, 1,   CHOP/DDIT3↓, 1,   ER Stress↓, 2,   GRP78/BiP↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,  

Migration(tgid=13) ⓘ

PROK2↑, 1,   TGF-β↓, 1,   α-SMA↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   BBB↝, 1,   CLDN4↑, 1,   IBI↑, 1,   MMP↓, 1,   OCLN↑, 1,   TJ↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 3,   ICAM-1↓, 1,   IL17↓, 2,   IL1β↓, 4,   IL23↓, 1,   IL6↓, 5,   IL8↓, 1,   Imm↑, 1,   Inflam?, 1,   Inflam↓, 9,   MyD88↓, 1,   NF-kB↓, 5,   RAGE↓, 2,   SOCS-3↓, 1,   TLR4↓, 1,   TNF-α↓, 6,   TRAF6↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 2,   BChE↓, 2,   BDNF↑, 1,   DHCR7↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 2,   BACE/β-secretase↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AHR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 1,   Dose?, 1,   Dose↝, 2,   eff↓, 1,   Half-Life↓, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALAT↑, 1,   AST↓, 2,   AST↑, 1,   IL6↓, 5,   RAGE↓, 2,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 3,   antiAll↑, 4,   AntiArt↑, 2,   AntiCan?, 1,   AntiCan↑, 2,   AntiDiabetic↑, 1,   AntiTum↑, 4,   cardioP↑, 2,   cognitive↑, 2,   hepatoP↓, 2,   hepatoP↑, 3,   Learn?, 1,   Learn↑, 3,   memory?, 1,   memory↑, 4,   neuroP↑, 7,   NP/CIPN↓, 1,   RenoP↝, 1,   Stroke↓, 4,   toxicity↓, 2,   toxicity↑, 3,   toxicity↝, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 3,   Bacteria↓, 2,   GutMicro↑, 1,   insect↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 136

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:322  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page